Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity NCT07785934 | UBT251 | Phase 1 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 48 | Dec 2026 | Aug 25, 2026 |
Safety and Efficacy of J147 in Acute Ischemic Stroke NCT07430917 | J-147 | Phase 2 | Recruiting | Abrexa Pharmaceuticals, Inc. | 196 | Mar 1, 2028 | Aug 24, 2026 |
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight NCT05929066 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 2,335 | Apr 6, 2026 | Aug 21, 2026 |
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes NCT06945419 | LY4086940 | Phase 1 | Completed | Eli Lilly and Company | 219 | Aug 5, 2026 | Aug 19, 2026 |
AT1001 for the Treatment of Long COVID NCT05747534 | Larazotide | Phase 2 | Completed | Massachusetts General Hospital | 107 | Jun 18, 2026 | Aug 18, 2026 |
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight NCT07710768 | UBT251 | Phase 1 | Recruiting | Novo Nordisk A/S | 44 | Apr 7, 2027 | Aug 18, 2026 |
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity NCT07400679 | Berobenatide | Phase 1 | Completed | Pfizer | 48 | Jul 2, 2026 | Aug 17, 2026 |
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction NCT05371496 | Semaglutide | Phase 4 | Completed | Mayo Clinic | 81 | Jul 17, 2026 | Aug 14, 2026 |
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight NCT06066528 | Survodutide | Phase 3 | Completed | Boehringer Ingelheim | 755 | Dec 12, 2025 | Aug 6, 2026 |
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide NCT07220642 | Cagrilintide | Phase 3 | Active not recruiting | Novo Nordisk A/S | 300 | May 11, 2027 | Aug 6, 2026 |
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight NCT06987513 | Pemvidutide | Phase 2 | Completed | Altimmune, Inc. | 100 | Jul 30, 2026 | Jul 31, 2026 |
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight NCT05929079 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 1,152 | Jun 16, 2026 | Jul 30, 2026 |
Kisspeptin Administration Subcutaneously to Patients With IHH NCT05896293 | Kisspeptin-10 | Phase 2 | Recruiting | Stephanie B. Seminara, MD | 36 | May 2028 | Jul 13, 2026 |
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity NCT07508241 | Berobenatide | Phase 1 | Active not recruiting | Pfizer | 22 | Jan 27, 2027 | Jul 9, 2026 |
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese NCT05616013 | Bimagrumab | Phase 2 | Completed | Eli Lilly and Company | 507 | May 16, 2024 | Jul 8, 2026 |
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06065540 | Cagrilintide | Phase 3 | Completed | Novo Nordisk A/S | 2,734 | Nov 19, 2025 | Jul 8, 2026 |
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight NCT06230523 | Eloralintide | Phase 2 | Completed | Eli Lilly and Company | 263 | May 30, 2025 | Jun 24, 2026 |
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415 | Retatrutide | Phase 3 | Active not recruiting | Eli Lilly and Company | 600 | Oct 2028 | Jun 9, 2026 |
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy NCT05337553 | Taldefgrobep alfa | Phase 3 | Active not recruiting | Biohaven Pharmaceuticals, Inc. | 269 | Sep 25, 2024 | Jun 1, 2026 |
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728 | Bimagrumab | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | Jan 16, 2026 | May 26, 2026 |
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) NCT06309992 | Survodutide | Phase 3 | Completed | Boehringer Ingelheim | 218 | Oct 9, 2025 | Apr 30, 2026 |
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function NCT07519135 | Berobenatide | Phase 1 | Recruiting | Pfizer | 26 | Jul 9, 2027 | Apr 23, 2026 |
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity NCT07395687 | UBT251 | Phase 2 | Recruiting | Novo Nordisk A/S | 333 | Jan 14, 2027 | Apr 21, 2026 |
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 1,100 | Jul 1, 2027 | Apr 7, 2026 |
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity NCT07505745 | MOTS-c | Phase 2 | Recruiting | Hudson Biotech | 120 | Feb 14, 2027 | Apr 1, 2026 |
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities NCT06662539 | Petrelintide | Phase 2 | Completed | Zealand Pharma | 493 | Sep 30, 2025 | Mar 23, 2026 |
Taldefgrobep Alfa in Adults With Overweight and Obesity NCT07281495 | Taldefgrobep alfa | Phase 2 | Active not recruiting | Biohaven Therapeutics Ltd. | 150 | Sep 2026 | Mar 20, 2026 |
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity NCT06200467 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 110 | Oct 22, 2025 | Mar 13, 2026 |
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems NCT06352411 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 42 | Sep 16, 2025 | Mar 13, 2026 |
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight NCT06066515 | Survodutide | Phase 3 | Completed | Boehringer Ingelheim | 726 | Dec 2, 2025 | Mar 12, 2026 |
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) NCT06354660 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 537 | Jan 22, 2026 | Mar 5, 2026 |
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight NCT06131437 | Cagrilintide | Phase 3 | Completed | Novo Nordisk A/S | 809 | Dec 8, 2025 | Feb 6, 2026 |
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese NCT06445075 | Apitegromab | Phase 2 | Completed | Scholar Rock, Inc. | 102 | Mar 4, 2025 | Jan 23, 2026 |
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam NCT05156320 | Apitegromab | Phase 3 | Completed | Scholar Rock, Inc. | 188 | Dec 18, 2024 | Jan 22, 2026 |
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee NCT05931367 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 445 | Nov 14, 2025 | Jan 21, 2026 |
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes NCT04982575 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 92 | Jul 7, 2022 | Dec 23, 2025 |
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus NCT05814107 | CT-996 | Phase 1 | Completed | Carmot Australia First Pty Ltd | 94 | Nov 7, 2025 | Nov 28, 2025 |
VK2735 for Weight Management Phase 3 NCT07104500 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 4,500 | Jul 1, 2027 | Nov 24, 2025 |
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) NCT05016882 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 698 | Dec 17, 2024 | Nov 19, 2025 |
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders NCT05633966 | Kisspeptin-10 | Phase 1 | Completed | Stephanie B. Seminara, MD | 13 | Aug 31, 2025 | Oct 3, 2025 |
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes NCT06901349 | Bimagrumab | Phase 2 | Withdrawn | Eli Lilly and Company | – | Jun 10, 2025 | Sep 24, 2025 |
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood NCT05896384 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 32 | Feb 14, 2025 | Apr 16, 2025 |
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) NCT04771273 | Survodutide | Phase 2 | Completed | Boehringer Ingelheim | 295 | Nov 9, 2023 | Dec 3, 2024 |
A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain NCT05298306 | AOD-9604 | Phase 1 | Completed | Lateral Pharma Pty Ltd | 26 | May 12, 2023 | Nov 27, 2024 |
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 NCT05296733 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 82 | Dec 29, 2023 | Aug 15, 2024 |
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. NCT03856047 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 706 | Mar 2, 2020 | Jul 5, 2024 |
AT1001 for the Treatment of COVID-19 Related MIS-C NCT05022303 | Larazotide | Phase 2 | Terminated | Massachusetts General Hospital | 12 | May 15, 2024 | Jun 13, 2024 |
A Study of LY3841136 in Healthy and Overweight Participants NCT05295940 | Eloralintide | Phase 1 | Completed | Eli Lilly and Company | 148 | Jan 25, 2024 | Apr 1, 2024 |
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight NCT04667377 | Survodutide | Phase 2 | Completed | Boehringer Ingelheim | 387 | Sep 15, 2022 | Nov 2, 2023 |
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy NCT02354781 | Follistatin 344 | Phase 1 / Phase 2 | Completed | Jerry R. Mendell | 3 | Nov 2017 | Oct 11, 2023 |